These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27766899)

  • 1. Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.
    Samineni D; Girish S; Li C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1557-1569. PubMed ID: 27766899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.
    Zheng S; McIntosh T; Wang W
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S75-84. PubMed ID: 25707966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.
    Kamath AV
    Drug Discov Today Technol; 2016; 21-22():75-83. PubMed ID: 27978991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens.
    Glassman PM; Balthasar JP
    MAbs; 2017; 9(2):297-306. PubMed ID: 27892793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.
    Lee JW; Kelley M; King LE; Yang J; Salimi-Moosavi H; Tang MT; Lu JF; Kamerud J; Ahene A; Myler H; Rogers C
    AAPS J; 2011 Mar; 13(1):99-110. PubMed ID: 21240643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
    Ternant D; Paintaud G
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S37-47. PubMed ID: 16187939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.
    Wang W; Wang X; Doddareddy R; Fink D; McIntosh T; Davis HM; Zhou H
    AAPS J; 2014 Jan; 16(1):129-39. PubMed ID: 24287601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.
    Chen X; Farrokhi V; Singh P; Ocana MF; Patel J; Lin LL; Neubert H; Brodfuehrer J
    MAbs; 2018 Jan; 10(1):62-70. PubMed ID: 29190188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated Bioanalytical Workflow for Ligand Binding-Based Pharmacokinetic Assay Development.
    Evans BR; Beck AG; Yeung L; Li A; Lee DH; Bateman KP; Chopra G
    Anal Chem; 2024 Jan; 96(1):488-495. PubMed ID: 38156369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic monoclonal antibody concentration monitoring: free or total?
    Kuang B; King L; Wang HF
    Bioanalysis; 2010 Jun; 2(6):1125-40. PubMed ID: 21083212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling.
    Tiwari A; Abraham AK; Harrold JM; Zutshi A; Singh P
    AAPS J; 2017 Mar; 19(2):510-519. PubMed ID: 28004347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab.
    Wu B; Joshi A; Ren S; Ng C
    J Pharm Sci; 2006 Jun; 95(6):1258-68. PubMed ID: 16637054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.
    Peng K; Xu K; Liu L; Hendricks R; Delarosa R; Erickson R; Budha N; Leabman M; Song A; Kaur S; Fischer SK
    MAbs; 2014; 6(6):1500-8. PubMed ID: 25484037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets.
    Davda JP; Hansen RJ
    MAbs; 2010; 2(5):576-88. PubMed ID: 20676036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
    Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics.
    Avery LB; Wade J; Wang M; Tam A; King A; Piche-Nicholas N; Kavosi MS; Penn S; Cirelli D; Kurz JC; Zhang M; Cunningham O; Jones R; Fennell BJ; McDonnell B; Sakorafas P; Apgar J; Finlay WJ; Lin L; Bloom L; O'Hara DM
    MAbs; 2018; 10(2):244-255. PubMed ID: 29271699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic.
    Myzithras M; Lin S; Radden L; Hess Kenny C; Cai Z; MacDonald A; Binetti R; Marlow M; Fracasso P; Gibson G; Bartlett C; Hawkins J; Hansel S
    MAbs; 2022; 14(1):2104153. PubMed ID: 35916739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.
    Yuan D; Rode F; Cao Y
    Eur J Pharm Sci; 2019 Oct; 138():105032. PubMed ID: 31394258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.